Delving into the Latest Updates on Mitotech SA with Synapse

A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study of Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and the Controlled Adverse Environmental (CAE®) Model for the Treatment of Dry Eye Syndrome

The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.

开始日期2019-12-20

申办/合作机构

Mitotech SA

[+1]

NCT03764735 / Completed临床3期

A Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution for the Treatment of Dry Eye Syndrome

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

开始日期2018-12-06

申办/合作机构

Mitotech SA

[+1]

NCT02121301 / Completed临床2期

Phase 2, Single-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophth Sol'n in the Environment and During Challenge in the Controlled Adverse Environment (CAE) Model for the Treatment of DES

The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.

开始日期2014-04-01

申办/合作机构

Mitotech SA

[+1]

100 项与 Mitotech SA 相关的临床结果

登录后查看更多信息

0 项与 Mitotech SA 相关的专利（医药）

登录后查看更多信息

100 项与 Mitotech SA 相关的药物交易

登录后查看更多信息

100 项与 Mitotech SA 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

1

批准上市

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Vizomitin	干眼症更多	批准上市
Plastoquinonyl decyl triphenylphosphonium ( Electron transport chain complex proteins )	干眼综合征更多	无进展